Compare BIIB & PRU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIIB | PRU |
|---|---|---|
| Founded | 1978 | 1875 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.5B | 39.0B |
| IPO Year | 1996 | 2001 |
| Metric | BIIB | PRU |
|---|---|---|
| Price | $249.28 | $121.73 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 36 | 18 |
| Target Price | ★ $268.26 | $115.53 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 4.58% |
| EPS Growth | N/A | ★ 33.20 |
| EPS | 2.66 | ★ 8.43 |
| Revenue | $9,890,600,000.00 | ★ $60,774,000,000.00 |
| Revenue This Year | $6.92 | N/A |
| Revenue Next Year | $1.91 | $1.51 |
| P/E Ratio | $94.29 | ★ $14.52 |
| Revenue Growth | ★ 2.22 | N/A |
| 52 Week Low | $160.36 | $91.89 |
| 52 Week High | $261.00 | $128.78 |
| Indicator | BIIB | PRU |
|---|---|---|
| Relative Strength Index (RSI) | 54.04 | 55.14 |
| Support Level | $240.00 | $116.52 |
| Resistance Level | $259.89 | $125.55 |
| Average True Range (ATR) | 7.29 | 2.73 |
| MACD | -1.09 | 0.12 |
| Stochastic Oscillator | 43.79 | 45.10 |
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Prudential Financial is one of the largest US life insurers, offering annuities, life insurance, and asset-management products. The United States and Japan are its two largest markets. Its US business contributed about 50% of adjusted 2025 earnings and includes institutional retirement (mostly pension risk transfer), individual retirement (annuities), group insurance, and individual life insurance. Its international business represented about 39% of adjusted earnings, with a strong market position in Japan, and the firm also has a presence in emerging markets like Brazil. The company's investment management business, PGIM, contributed approximately 11% of its 2025 adjusted earnings. PGIM had around $1.47 trillion in assets under management at the end of fourth-quarter 2025.